

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 March 2025 (27.03.2025)



(10) International Publication Number
WO 2025/064197 A1

(51) International Patent Classification:
C07D 401/14 (2006.01) A61K 31/4545 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/US2024/044649

(22) International Filing Date:
03 October 2024 (03.10.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
202311058934 02 September 2023 (02.09.2023) IN

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY**
[US/US]; Route 206 and Province Line Road, Princeton, NJ
08543 (US).

(72) Inventors: **SHIRUDE, Pravin, Sudhakar**; c/o BRIS-
TOL-MYERS SQUIBB INDIA PRIVATE LIMITED, The
Indiabulls Finance Centre, 6th Floor, Tower 1, Senapati Ba-
pat Marg, Elphinstone (W), Mumbai 400 013 (IN). **SHIM-
PUKADE, Bharat, Dinkar**; c/o Syngene International
Limited, Biocon Special Economic Zone, Biocon Park, Plot
Nos. 2&3, Bommasandra Industrial Area IV Phase, Jigani
Link Road, Bangalore 560099 (IN). **PENMETSA, Suresh,
Babu, Vishwa, Krishna**; c/o Syngene International Limit-
ed, Biocon Special Economic Zone, Biocon Park, Plot Nos.
2&3, Bommasandra Industrial Area IV Phase, Jigani Link
Road, Bangalore 560099 (IN).

(74) Agent: **GREENBLATT, Gary, D.** et al.; Bristol-Myers
Squibb Company, Route 206 and Province Line Road,
Princeton, NJ 08543 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))


Published:

- with international search report (Art. 21(3))
- the filing date of the international application is within two
months from the date of expiration of the priority period
(Rule 26bis.3)
- with sequence listing part of description (Rule 5.2(a))



WO 2025/064197 A1

(54) Title: SUBSTITUTED AZETIDINYL OXOISOINDOLINYL PIPERIDINE-2,6-DIONE COMPOUNDS



(I)

(57) Abstract: Disclosed are compounds of Formula (I): (I) or stereoisomers, tautomers, or salts thereof, wherein R is defined here-
in. Also disclosed are methods of using such compounds to de-
crease the levels of Ikaros protein, Helios protein, Aiolos protein,
and Eos protein; and pharmaceutical compositions comprising such
compounds. These compounds are useful in the treatment of viral
infections and proliferative disorders, such as cancer.